Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), joined partner The Chopra Foundation in recognizing World Mental Health Day, which was Monday, Oct. 11, 2022. The two organizations are working together to research the … Continue reading →

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today provided an update on its intellectual property (“IP”) progress in support of its research and development strategy. According to the update, Cybin continues to … Continue reading →

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its wholly owned subsidiary, Cybin IRL Limited, have signed a deal with Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) to acquire an exclusive … Continue reading →

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(TM). The company today announced its participation in upcoming conferences taking place in September and October 2022. The company’s CEO Doug Drysdale participated in a … Continue reading →

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has successfully reached key research and development (“R&D”) milestones that were identified in the company’s acquisition agreement of Adelia Therapeutics in 2020. The milestones were reached … Continue reading →

First dose is administered as first-ever novel psilocybin analog enters clinical development Cybin believes CYB003 has potential to successfully address the challenges and limitations of oral psilocybin The high level of participant interest in the study indicates a significant unmet … Continue reading →

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is making significant headway with its flagship deuterated psilocybin analog, CYB003. “CYB003 has the potential to effectively treat … Continue reading →

Cybin (NYSE American: CYBN) (NEO: CYBN) is a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions. The company is on the leading edge of a transformation that has seen the status of psilocybin … Continue reading →

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(TM). The company today announced that its wholly controlled subsidiary, Adelia Therapeutics Inc., has achieved the milestone identified as Y2, Q4(ii) as contemplated by the … Continue reading →

A new study shows promise in treating alcohol addiction with psychedelic mushroom compound, psilocybin These results align with efforts and expectations of Cybin, a leading ethical biopharmaceutical company championing psilocybin After receiving FDA approval, the company is moving forward with … Continue reading →